Exonate develops and licenses Vascular Endothelial Growth Factors (VEGF) control agents that may be used as therapeutics in areas such as pain control, macular degeneration and cancer.
Exonate’s research in this area has identified therapeutic candidates for wet Age Related Macular Degeneration that can be administered as a simple eye drop, thereby over-coming the unpleasant need for monthly injections in the eye.
Competing injectable anti-VEGFdirected therapy currently constitutes the gold-standard treatment for wet Age Related Macular Degeneration (wAMD) and other neovascular diseases of the eye.
© 2020 Nottingham Technology Ventures Limited.
All rights reserved.
Registered in England number 04477457
Registered office address
University Of Nottingham Kings Meadow Campus, Lenton Lane, Nottingham, England, NG7 2NR
Nottingham Technology Ventures Limited
The Ingenuity Centre
University of Nottingham Innovation Park
Triumph Road
Nottingham
NG7 2TU